Solubility, Polymorphism, Crystallinity, Crystal Habit, and Drying Scheme of (R, S)-(±)-Sodium Ibuprofen Dihydrate - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Solubility, Polymorphism, Crystallinity, Crystal Habit, and Drying Scheme of (R, S)-(±)-Sodium Ibuprofen Dihydrate
The racemic compound (R, S)-(±)-ibuprofen is a popular and well understood active pharmaceutical ingredient, but it has several disadvantageous formulation properties such as poor solubility, low melting point, and potential esterification with excipients containing an hydroxyl group. The authors investigate the use of an (R, S)-(±)-ibuprofen salt to evaluate these problems using various analytical methods to determine the polymorphism, crystallinity, and drying scheme.


Pharmaceutical Technology



Figure 1
The racemic compound (R,S)-(±)-ibuprofen or (R, S)-(±)-2-(4-isobutylphenyl) propionic acid is a popular active pharmaceutical ingredient (API) in analgesic, anti-inflammatory, and antipyretic therapies (1) with abundant information about the compound provided in the literature (2–11). Ibuprofen is marketed as a racemate. The enantiomer (S)-(+)-ibuprofen is the active agent and the other enantiomer, (R)-(–)-ibuprofen, is partially converted into (S)-(+)-ibuprofen in humans. (R,S)-(±)-ibuprofen has several disadvantageous formulation properties such as poor water solubility of less than 1 mg/mL at 25 °C, a low melting point of 77 °C, and possible esterification with excipients containing a hydroxyl group (1). These problems can be easily overcome by using an (R,S)-(±)-ibuprofen salt such as the racemic compound (R,S)-(±)-sodium 2-(4-isobutyl–phenyl) propionate dihydrate or (R, S)-(±)-sodium ibuprofen dihydrate (see Figure 1), whose potential values over (R,S)-(±)-ibuprofen make the study of its solubility, polymorphism, crystallinity, crystal habit, and drying scheme meaningful (12).

In this study, the solubility of (R, S)-(±)-sodium ibuprofen dihydrate solids at 25 °C was determined in 23 solvents using a robust and scalable initial solvent-screening method (13). Good solvents were identified, and the solubility curves of the solids in various good solvents were constructed. Good solvents were defined as solvents in which the solubility of racemic (R, S)-(±)-sodium ibuprofen dihydrate had a solubility of < 1 mg/mL at 25 °C. All solids were produced from the supersaturated solution of the good solvents by temperature cooling from 60–25 °C.

Differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and powder X-ray diffraction (PXRD) determined the polymorphism, crystallinity, and drying scheme of the solid samples (14). Optical microscopy (OM) and scanning electron microscopy (SEM) were used for crystal-habit imaging. The solids' solubilities and crystal habits were related to the solvent microscopic properties of dispersion forces (δd) polar forces (δp), and hydrogen bonding (δh) by the Hansen model adopted from the paint industry at 25 °C (15).

Solvent liquids generally are held together by van der Waals forces, which are electromagnetic interactions among molecules. The strength of van der Waals forces is directly reflected by the heat of vaporization (ΔHv). ΔHv can be translated into a correlation between vaporization and the solubility behavior because the types of intermolecular attractive forces needed to be overcome to vaporize a solvent liquid are the same as those that must be overcome to dissolve it. The Hildebrand numerical value (δt[Pa1/2 ]) of the solvency behavior of a specific solvent was invented as a function of ΔHv (15) in the following:











in which R is the gas constant (8.314 J/mol • K), T is the temperature (measured in K), and Vm is the molar volume (measured in m3 /mol).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
25%
To select processes for both new and legacy products
20%
Do not use QbD
23%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here